186 related articles for article (PubMed ID: 31828273)
1. The diagnostic power of circulating micro ribonucleic acid 34a in combination with cancer antigen 15-3 as a potential biomarker of breast cancer.
Raheem AR; Abdul-Rasheed OF; Al-Naqqash MA
Saudi Med J; 2019 Dec; 40(12):1218-1226. PubMed ID: 31828273
[TBL] [Abstract][Full Text] [Related]
2. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
4. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
Park BJ; Cha MK; Kim IH
BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of miRNA-9 and miRNA-34a as potential biomarkers for diagnosis of breast cancer in Iranian women.
Orangi E; Motovali-Bashi M
Gene; 2019 Mar; 687():272-279. PubMed ID: 30468908
[TBL] [Abstract][Full Text] [Related]
6. Serum microRNA-155 as a potential biomarker to track disease in breast cancer.
Sun Y; Wang M; Lin G; Sun S; Li X; Qi J; Li J
PLoS One; 2012; 7(10):e47003. PubMed ID: 23071695
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers.
Swellam M; Ramadan A; El-Hussieny EA; Bakr NM; Hassan NM; Sobeih ME; EzzElArab LR
J Cell Biochem; 2019 Aug; 120(8):12321-12330. PubMed ID: 30825229
[TBL] [Abstract][Full Text] [Related]
10. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
11. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
12. FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer.
Mi J; Zhang H; Cao W; Yuan C
Medicine (Baltimore); 2023 Oct; 102(42):e35361. PubMed ID: 37861518
[TBL] [Abstract][Full Text] [Related]
13. Impact of Breast Tumor Onset on Blood Count, Carcinoembryonic Antigen, Cancer Antigen 15-3 and Lymphoid Subpopulations Supported by Automatic Classification Approach: A Pilot Study.
Baselice S; Castaldo R; Giannatiempo R; Casaretta G; Franzese M; Salvatore M; Mirabelli P
Cancer Control; 2021; 28():10732748211048612. PubMed ID: 34620015
[TBL] [Abstract][Full Text] [Related]
14. Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA.
Zaleski M; Kobilay M; Schroeder L; Debald M; Semaan A; Hettwer K; Uhlig S; Kuhn W; Hartmann G; Holdenrieder S
Oncotarget; 2018 Apr; 9(32):22523-22536. PubMed ID: 29854296
[TBL] [Abstract][Full Text] [Related]
15. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
[TBL] [Abstract][Full Text] [Related]
16. Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer.
Zuo X; Chen L; Liu L; Zhang Z; Zhang X; Yu Q; Feng L; Zhao X; Qin T
Tumour Biol; 2016 Jan; 37(1):1309-17. PubMed ID: 26289852
[TBL] [Abstract][Full Text] [Related]
17. A novel serum metabolome score for breast cancer diagnosis.
Rashed R; Darwish H; Omran M; Belal A; Zahran F
Br J Biomed Sci; 2020 Oct; 77(4):196-201. PubMed ID: 32546046
[TBL] [Abstract][Full Text] [Related]
18. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis.
Fu Y; Li H
Med Sci Monit; 2016 Sep; 22():3154-62. PubMed ID: 27596019
[TBL] [Abstract][Full Text] [Related]
19. 8-Hydroxy-2'-deoxyguanosine as a Discriminatory Biomarker for Early Detection of Breast Cancer.
Nour Eldin EEM; El-Readi MZ; Nour Eldein MM; Alfalki AA; Althubiti MA; Mohamed Kamel HF; Eid SY; Al-Amodi HS; Mirza AA
Clin Breast Cancer; 2019 Apr; 19(2):e385-e393. PubMed ID: 30683611
[TBL] [Abstract][Full Text] [Related]
20. Plasma MicroRNA-34a as a Potential Biomarker for Early Diagnosis of Esophageal Cancer.
Lin Y; Lin Z; Fang Z; Li H; Zhi X; Zhang Z
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
